Basilea Pharmaceutica AG (OTCMKTS:BPMUF) Short Interest Up 114.5% in May

Basilea Pharmaceutica AG (OTCMKTS:BPMUF) saw a significant increase in short interest in the month of May. As of May 29th, there was short interest totaling 1,171 shares, an increase of 114.5% from the May 14th total of 546 shares. Currently, 0.0% of the shares of the company are short sold. Based on an average daily volume of 2 shares, the short-interest ratio is presently 585.5 days.

Basilea Pharmaceutica Stock Performance

Shares of OTCMKTS BPMUF opened at $60.28 on Monday. The company has a current ratio of 5.11, a quick ratio of 4.68 and a debt-to-equity ratio of 0.59. Basilea Pharmaceutica has a 1-year low of $59.29 and a 1-year high of $74.00. The business’s 50 day moving average is $67.58 and its 200-day moving average is $67.87.

Basilea Pharmaceutica Company Profile

Basilea Pharmaceutica AG is a Swiss biopharmaceutical company headquartered in Basel, specializing in the development and commercialization of innovative treatments for hospital‐treated diseases. The company’s research is focused primarily on anti‐infectives and oncology, with a portfolio that spans both marketed products and early‐ to late‐stage pipeline candidates. Basilea leverages medicinal chemistry expertise to address critical medical needs in fungal infections, bacterial infections and cancer.

Among its lead products is isavuconazole, a broad‐spectrum antifungal agent marketed under the trade name Cresemba.